Low testosterone levels linked to reduced risk of prostate cancer

November 6, 2017, Cancer Research UK
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Men with unusually low amounts of testosterone in their blood are around 20% less likely to develop prostate cancer, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

Scientists from the University of Oxford conducted the largest analysis of hormones and prostate risk to date. The study – funded by Cancer Research UK – looked at blood samples from around 19,000 men aged 34-76 years, collected between 1959 and 2004. Of these men 6,900 went on to develop prostate cancer.

The researchers divided the 19,000 men into ten groups – ranging from men with the lowest amount of testosterone in their blood to those with the highest, and compared their prostate cancer risk.

They found that men in the group with the lowest levels of testosterone were significantly less likely to develop prostate cancer compared to all other men. Yet interestingly, when men in this group do get prostate cancer, they are 65% more likely to develop an aggressive form of the disease compared to all other men. For the men in the remaining nine groups, testosterone was not associated with prostate cancer risk.

This is the first study to look at whether unusually low influence the risk of developing prostate cancer. The findings are important because scientists know very little about the risk factors for developing the disease, including the role a man's biology might play.

Prostate cancer needs testosterone to grow. Nearly all prostate cancers that spread have overactive testosterone receptors. Hormone therapy – the standard care for treatment of prostate cancer – blocks or lowers the amount of testosterone in the body.

This is the first population study to support the hypothesis that testosterone receptors on quickly become saturated. It appears that once that level has been reached, further increases in testosterone do not increase cancer growth. This could explain why only men with the lowest amount of the hormone, which falls below the saturation point, have a reduced risk compared to men in every other group.

Professor Tim Key, co-author of the study from the University of Oxford, said: "This is an interesting biological finding that could help us understand how prostate cancer develops and progresses. Until now, we didn't have a clear idea of the role played in . This is the first population study to support the theory that risk is lowered below a certain threshold of the hormone."

Professor Matt Seymour, the NCRI's clinical research director, said: "Hormones play a fundamental role in prostate function and cancer's development and progression. We know very little about the risk factors for prostate cancer, so this research raises some interesting questions for further research.

"In future, these results could be important in helping to devise an approach to reducing men's risk of developing the disease."

Professor Malcom Mason, Cancer Research UK's prostate cancer expert, said: "Testosterone's role in prostate cancer's development has been a hotly debated area of research, so it's great to see some strong evidence. This puts another piece of the jigsaw into place in terms of understanding the biology of what causes cancer.

"In future, it's possible that this could help unravel ways to diagnose and treat fatal before they can do any harm, but that's very far down the line."

Explore further: Low testosterone levels may indicate worsening of disease for men with prostate cancer

More information: Low circulating free testosterone is associated with reduced incidence of prostate cancer: A pooled analysis of individual participant data from 20 prospective studies. abstracts.ncri.org.uk/abstract … prospective-studies/

Related Stories

Low testosterone levels may indicate worsening of disease for men with prostate cancer

May 5, 2014
For men with low-risk prostate cancer, low levels of testosterone may indicate a worsening of their disease. That's the conclusion of a new study published in BJU International. The findings may help physicians identify patients ...

Body size and prostate cancer risk

July 14, 2017
Prostate cancer is the most common cancer in men in Europe and the second most frequently diagnosed cancer in men worldwide.

Are men with a family history of prostate cancer eligible for active surveillance?

April 6, 2017
Active surveillance—careful monitoring to determine if or when a cancer warrants treatment—is an increasingly prevalent choice for prostate cancer, but it's unclear if the strategy is appropriate for men with a family ...

New findings concerning hereditary prostate cancer

July 11, 2016
It is a well-known fact that men with a family history of prostate cancer run an increased risk of developing the disease. The risk for brothers of men with prostate cancer is doubled. But a doubled risk of what, exactly? ...

Study shows testosterone therapy does not increase aggressive prostate cancer risk

October 5, 2015
A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive ...

Study suggests testosterone therapy does not raise risk of aggressive prostate cancer

May 7, 2016
Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer.

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.